14487-45-7

Usage

Uses

Used in Pharmaceutical Industry:
H-DL-GLU(OME)-OH is used as a therapeutic agent for patients with liver disease accompanied by encephalopathy, due to its role as a neurotransmitter in the central nervous system.
Used in Neurological Applications:
H-DL-GLU(OME)-OH is used as a neurotransmitter for cone photoreceptors in the human brain, playing a crucial role in the proper functioning of the central nervous system.
Used in Research and Development:
As an amino acid derivative, H-DL-GLU(OME)-OH is utilized in research and development for its potential applications in understanding neurological processes and developing new treatments for related conditions.

InChI:InChI=1/C6H11NO4/c1-11-5(8)3-2-4(7)6(9)10/h4H,2-3,7H2,1H3,(H,9,10)/p-1/t4-/m0/s1

Upstream product

• 3343-28-0 N-phthaloylglutamic acid anhydride 
• 67-56-1 methanol 
• 617-65-2 Glutamic acid 
• 138036-14-3 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-5-methoxy-5-oxopentanoic acid 

Downstream Products

• 125090-25-7 α-t-butyl γ-methyl N-trityl-(RS)-glutamate 
• 118545-57-6 t-butyl 2-tritylamino-4-carbomethoxy-5-hydroxy-5-phenyl-(2RS)-pentanoate 
• 1380547-37-4 (R)-2-benzamido-2-((R)-3-oxo-1-phenylbutyl)pentanedioic acid 
• 1380547-38-5 (R)-dimethyl 2-benzamido-2-((R)-3-oxo-1-phenylbutyl)pentanedioate 
• 1380547-27-2 methyl 3-((R)-4-((R)-1-(3,4-dimethoxyphenyl)-3-oxobutyl)-5-oxo-2-phenyl-4,5-dihydrooxazol-4-yl)propanoate 
• 1380547-26-1 methyl 3-((R)-5-oxo-4-((R)-3-oxo-1-phenylbutyl)-2-phenyl-4,5-dihydrooxazol-4-yl)propanoate 
• 23577-92-6 γ-methyl-α-tert-butyl ester of N-carbobenzoxyglutamic acid 
• 4652-65-7 2-Benzyloxycarbonylamino-pentanedioic acid 5-methyl ester 
• 1323405-59-9 3-(4-((4-((4-methylpiperazin-1-yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 1323407-86-8 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 
• 112159-16-7 2-((tert-butoxycarbonyl)amino)-5-methoxy-5-oxopentanoic acid 
• 138036-14-3 2-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-5-methoxy-5-oxopentanoic acid 

Relevant academic research and scientific papers

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.

ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.

ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE

Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3e (CD3) provided herein, in treating, preventing or managing multiple myeloma.

METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE

A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

Stereospecific Amino Acid Synthesis; Preparation of the γ-Anion derived from Glutamic Acid

Reaction of α-t-butyl γ-methyl N-trityl-L-glutamate (7) with lithium isopropylcyclohexylamide in hexane leads to the specific formation of the γ-ester enolate, a potential synthetic equivalent to the γ-anion synthon for stereospecific α-amino acid synthesis.